Skip to main content
. 2021 Jul 28;22(15):8090. doi: 10.3390/ijms22158090

Table 4.

Known high TdP risk drugs and CYP strong inhibitors interactions.

CYP Metabolizer Drug with a Known TdP Risk Type X Interactions When Combined with (High Risk of QT Prolongation)
CYP3A4 Amiodarone Voriconazol
Indinavir
Ritonavir
Saquinavir
Clarithromycin
Disopyramide Itraconazol
Clarithromycin
Ketoconazol (systemic)
Saquinavir
Telithromycin
Dofetilide Clarithromycin
Itraconazole
Ketoconazole
Dronedarone Clarithromycin
Ceritinib
Indinavir
Itraconazole
Nefazodone
Ritonavir
Saquinavir
Telithromycin
Voriconazole
Ibutilide Clarithromycin
Quinidine Clarithromycin
Itraconazol
Ketoconazol
Ritonavir
Saquinavir
Voriconazole
Azithromycin Certinib
Clarithromycin
Saquinavir
Voriconazole
Clarithromycin Saquinavir
Erythromycin Saquinavir
Cloroquine Ceritinib
Clarithromycin
Saquinavir
Voriconazole
Chlorpromazine Certinib
Saquinavir
Voriconazol
Clarithromycin
Haloperidol Saquinavir
Levomepromazine Ritonavir
Saquinavir
Escitalopram -
Ondansetron -
Cisapride Ceritinib
Clarithromycin
Indinavir
Itraconazole
Ketoconazole
Nefazodone
2D6 Flecainide
Ibutilide Quinidine
Procainamide Quinidine
Chloroquine -
Hydroxychloroquine -
Chlorpromazine -
Haloperidol -
2C19 Citalopram -
Escitalopram -
Chlorpromazine -

The drugs metabolized by a given CYP were crossed with the drugs known inhibit the respective CYP (See Supplementary Table S1) taken from [91]. Known TdP risk drugs were taken from CredibleMeds® list of known risk of TdP drugs [24]. Drug interactions were analyzed for the potential drug interactions using Lexi-Interact™ Online available on the website www.uptodate.com (accessed on 10 June 2021) [89].